Clinical trials: ADHD
ADHD Specifically With Executive Function Impairment
Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function…
- Trial name
- NCT01101022
- Testing
- SPD489
- Where
- 39 sites in United States
- Volunteers
- 161 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00610441
- Testing
- MK-8777
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention-Deficit/Hyperactivity Disorder, ADHD
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00429091
- Testing
- ABT-894, atomoxetine
- Where
- 22 sites in United States
- Volunteers
- 243 people
- Sponsor
- Abbott
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
The study is designed to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy (in the morning).
- Trial name
- NCT00386581
- Testing
- atomoxetine
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
SPD544 High Strength Bioequivalence Study
The purpose of this study is to assess bioequivalence of 2 capsule strengths.
- Trial name
- NCT01183234
- Testing
- SPD544, Methylphenidate hydrochloride
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
ADHD
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
- Trial name
- NCT02168127
- Testing
- Drug: PRC-063, PRC-063
- Where
- 35 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890240
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Adult Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
- Trial name
- NCT03324581
- Testing
- OPC-64005, Atomoxetine
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
- Trial name
- NCT03247530
- Testing
- 100mg SPN-812, 200mg SPN-812
- Where
- 7 sites in United States
- Volunteers
- 477 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Vestibular Disorder, Educational Problems
VestibulOTherapy: Vestibular Impact on Learning
Research Question: Will daily engagement in activities tailored to the evidence-based vestibular research result in improved attention and learning outcomes for children ages 6-9 years of age after an 8-week classroom-based…
- Conditions
- Vestibular Disorder, Educational Problems, Attention Deficit Disorder
- Trial name
- NCT05793216
- Testing
- VestibulOTherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VestibulOTherapy
Impulsive Aggression Comorbid With ADHD in Children
Open-Label, Extension Study to 810P202
Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with…
- Trial name
- NCT01416064
- Testing
- Molindone
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Naltrexone, Methylphenidate Abuse
Study for Naltrexone on the Abuse Potential of Methylphenidate
The current abuse liability study aims to assess the potential for co-administration of naltrexone (NTX) to reduce the abuse potential of methylphenidate (MPH).
- Trial name
- NCT03769064
- Testing
- Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Avekshan LLC
Attention Deficit Hyperactivity Disorder
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity…
- Trial name
- EMD (NCT01127646)
- Testing
- Atomoxetine, Osmotic-release oral system methylphenidate
- Where
- 14 sites in Netherlands, Spain and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company